La Comisión  ha ampliado la fecha límite de presentación de proyectos de las convocatorias abiertas de H2020  hasta el 15 de abril. Esto no aplica a las convocatorias de EIC Accelerator ni IMI.

  • EIC Accelerator: startups and SMEs with technologies and innovations tackling COVID-19 outbreak can apply for fast-track EU funding by 5pm on 18 March. This is a bottom-up call (i.e. there are no predefined thematic priorities and applicants with Coronavirus relevant innovations) which has a budget of € 164 m. 
  • IMI (Innovative Medicines Initiatives) partnership: this is a fast-track call of € 45 m (i.e. total investment of up to € 90 m with commitment from pharmaceutical industry) inviting project proposals for treatments and diagnostics combatting coronavirus infections. The deadline for submitting proposals is 31 March. Through the current IMI portfolio, the following projects are actively involved in the COVID-19 outbreak:
    • Zoonotic anticipation and preparedness initiative (ZAPI): this project aims to create new platforms and technologies that will facilitate a fast, coordinated, and practical response to new infectious diseases as soon as they emerge. Their focus includes other coronaviruses, potentially allowing for technology and expertise transfer for the current outbreak.
    • Combatting bacterial resistance in Europe (COMBACTE-NET): this is dedicated to building strong clinical laboratory and research networks across Europe. It has established a pan-European network of clinics and hospitals for more efficient and speedy testing of novel treatment strategies, a network of microbiology laboratories to support the diagnosis of patients and identify the most appropriate treatments as well as to validate diagnostics tests. An epidemiological network has also been established in the COMBACTE-MAGNET project that harmonises and connects various European systems of disease surveillance.
  • Emergency call (closed): this H2020 call of € 47.5 m was launched to fund research on COVID-19 vaccine development, treatment and diagnostics  The deadline was 12 February. 
  • PREPARE project: this project has initiated and implemented clinical research studies on coronavirus across Europe. The EU is granting € 24 m.
  • European Virus Archive (EVA-GLOBAL or EVAg): this is a virtual collection for human, animal and plant viruses, which has already responded to more than 1200 requests to provide access to the necessary material for diagnosing coronavirus infection. The EU is granted € 12.2 m.
  • Global research collaboration for infectious disease preparedness (GloPID-R): this network is mobilised to facilitate a rapid and effective response to this outbreak, through the coordination of research agenda and addressing priority research needs. EU grant to support GloPID-R 2 is €1.3 m.
  • VEO project: this started in January 2020, working on diagnostics and data mining, including the use of social media. The EU is granting 15 m. 
  • MOOD project: this project on data mining and eliding modelling started in January 2020. The EU is granting 14 m.
  • CureVac: this German vaccine developer company has received € 80 m to scale u development and production of a vaccine against the COVID-19. The support comes in form of an EU guaranteed of a currently assessed EIB loan of an identical amount, in the framework of the InnovFin infectious disease finance facility under H2020.
  • HPC Centre of Excellence for Computational Biomolecular Research ‘BioExcel‘: the applications can be used for on-demand, large-scale virtual screening of potential medical compounds. The applicability depends on the specific case of pandemic cause.
  • EuroHPC Joint Undertaking: its access policy foresees prioritised and imm
  • ediate access to its supercomputers for emergency as is the case in pandemic crises.
  • African coaLition for Epidemic Research, Response and Training (ALERRT) and the Pan-African Network for Rapid Research, Response, Relief and Preparedness for Infectious Diseases Epidemics (PANDORA-ID-NET): these projects are developed under the European and Developing Countries Clinical Trials Partnership (EDCTP 2).

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *